Liver Fibrosis Treatment Market Overview By New Technology, Demand And Scope 2023 to 2033

 The global Liver Fibrosis Treatment Market is anticipated to exceed a remarkable valuation of US$ 16.43 billion in 2023, with a compound annual growth rate (CAGR) of 11% projected from 2023 to 2033.

The rising prevalence of undesirable outcomes such as hepatitis B or C virus infection, an impaired immune system due to co-infection with human immunodeficiency virus (HIV), and the use of immunosuppressive medicines following a liver transplant is expected to fuel growth in the liver fibrosis treatment market throughout the forecast period.

Get a Full PDF Sample Copy of the Latest Reports @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16529

Increased research by the private research government to improve treatments for liver fibrosis and other fatty liver diseases is expected to spur expansion in the liver fibrosis treatment market. Expansion of pre-clinical and clinical studies, as well as development by prominent stakeholders, to establish creative treatment options in the liver fibrosis regime, are expected to propel global liver fibrosis treatment growth in the future.



In March 2018, the US Food and Drug Administration granted Orphan Drug Designation to PTG-300, a subcutaneous injectable developed by Protagonist Therapeutics, Inc. The PTG-300 is currently being studied for the treatment of beta-thalassemia and has the potential to cure liver fibrosis.

Hepatic Fibrosis Management is a condition in which the liver develops scar tissue as a result of long-term damage.

Key Takeaways from the Market Study

  • From 2018 to 2022, sales increased significantly at a CAGR of 9.8%.
  • According to World Health Organization data released in 2022, 296 million people were estimated to have chronic hepatitis B infection in 2019, with 1.5 million new infections every year.
  • The Asia Pacific market is expected to grow at the fastest rate of 11.1%.
  • The hepatotropic drug segment was the dominant segment in 2021, with a market share of 29.5%.
  • The global market for Liver Fibrosis Treatment is expected to be worth US$ 46.65 billion by 2033.

“The growing incidence of adverse reactions such as hepatitis B or C virus infection, an impaired immune system due to co-infection with human immunodeficiency virus (HIV), and the use of immunosuppressive medicines following a liver transplant are expected to fuel expansion in the liver fibrosis treatment market over the forecast period.” says FMI’s analyst

To learn more about this report @ https://www.futuremarketinsights.com/reports/liver-fibrosis-treatment-market

Key Market Players

More Valuable Insights AvailKey players in the Liver Fibrosis Treatment market are Gilead Sciences, Inc., Merck & Co., Inc., Bristol-Myers Squibb, Johnson and Johnson, Novartis AG, Vertex Pharmaceuticals Incorporated, Pfizer Inc., FibroGen, Inc., Inventiva Pharma, Pharmaxis Limited.

  • In March 2019, Gilead Sciences Inc. launched the HepConnect Program to Reduce Hepatitis C Infections in Greater Appalachia.
  • It was disclosed in December 2020 that Aligos Therapeutics Inc. will collaborate with Merck & Co. Inc. to create a therapy for liver fibrosis treatment.

Key Segments Profiled in the Liver Fibrosis Treatment Industry Survey

By Treatment Type:

  • Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
  • ACE Inhibitors
  • Hepatotropic Drug
  • Others

By Condition:

  • Chronic Liver Diseases
  • Hepatitis C
  • Nonalcoholic Steatohepatitis

By End User:

  • Hospitals
  • Specialty Clinics
  • Others

Comments

Post a Comment

Popular posts from this blog

Pet Diabetes Care Devices Market Report | Size, Growth, Demand, Scope and Forecast to 2032

  The global  Pet Diabetes Care Devices Market  is expected to grow at a  6.5%  CAGR, reaching  US$ 4 billion  by 2032, up from  US$ 2 billion  in 2021. “The number of pets with diabetes, the number of adopted pets, and the number of overweight pets are all driving the market forward.” Get Full Access @ https://www.futuremarketinsights.com/reports/pet-diabetes-care-devices-market The domestication of animals is leading to a lack of insulin production in them. The limited flow of glucose to the cell can be termed diabetes. This chronic disease is a major concern for pet owners and needs to be taken care of. This concern leads to the expansion of the pet diabetes care devices market. Devices like the alphatrak blood glucose meter are in use as they help the pet owners monitor the pet’s health. The increased number of people adopting pets and then domesticating them around in their households, treating and caring for them as f...
Read more

Human Immunodeficiency Virus Type 1 (HIV 1) Market Opportunity, Competitive Analysis, Future Prospects to 2033

Image
  The global Human Immunodeficiency Virus Type 1 (HIV 1) Market is predicted to exceed a remarkable valuation of US$ 34.83 Billion in 2023, with a compound annual rate of growth (CAGR) of 6% estimated from 2023 to 2033. The Institute for Health Metrics and Evaluation attributes the industry's growth to the soaring incidence rate of HIV-1 infection, which, unlike the deaths caused from this viral illness, has not updated substantially over time. Get Full Access @ https://www.futuremarketinsights.com/reports/human-immunodeficiency-virus-type-1-hiv1-market It affected approximately 37 million people worldwide. Furthermore, antiretroviral therapeutic interventions for disease management are only available to half of this population. HIV-1 is the more common of the two types of human immunodeficiency virus, accounting for approximately 96% of all infections globally. The prevalence of HIV is rising at an alarming rate. The World Health Organization (WHO) estimates that 33.0 million...
Read more

Clostridium Diagnostics Market in US is anticipated to secure a market value worth US$ 2.7 Billion by 2032 | FMI

Image
  The global Clostridium Diagnostics Market is expected to grow at a CAGR of 12.2% during the forecast period, from US$ 2.5 billion in 2022 to US$ 7.8 billion by 2032. The market grew at a CAGR of 13.6% between 2015 and 2021. The rising prevalence of clostridium-related diseases, as well as increased campaigns to educate people about the condition, are driving the market growth. To learn more about this report @ https://www.futuremarketinsights.com/reports/clostridium-diagnostics-market here has been an increased focus of players in the market to offer vaccines, which can augment the market size in the forecast period. For instance, in March 2022, Japan launched a new center, with a budget of US$ 1.6 Billion, to support vaccine and drug projects as a part of a larger scheme to tackle infectious diseases. SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects. Awareness camp...
Read more